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Background and aims: Germline mutations in mismatch repair (MMR) genes cause a greatly increased
risk of cancer of the gastrointestinal and female reproductive tracts (hereditary non-polyposis colorectal
cancer (HNPCC)). Loss of MMR expression is common in colorectal cancer (CRC) overall. Such loss is
assumed to be acquired predominantly, although a population of CRC cases will include individuals with
unrecognised MMR mutations. This study examines the association between MMR gene expression and
family history of cancer among the CRC population.
Methods: Individuals with CRC were identified from two well characterised populations: (1) consecutive
hospital patients (n = 644) and (2) a population based cases series (n = 249). CRC was examined for
expression of hMLH1 and hMSH2 using immunohistochemistry, and expression was related to family
history using logistic regression.
Results: hMLH1 and hMSH2 expression was assessed in 732 CRCs with 8% showing loss of expression.
No association was seen overall for hMLH1 or hMSH2 expression and family history of CRC. Loss of
hMSH2 was predicted by family history of extracolonic cancer (odds ratio (OR) 5.78 (95% confidence
interval (CI) 0.95–35.18)) and family history suggestive of HNPCC (OR 27.84 (95% CI 4.37–177.56)).
Loss of hMLH1 was not predicted by family history of extracolonic cancer or a family history suggestive of
HNPCC but was for a family history of at least two affected relatives (OR 4.88 (95% CI 1.25–19.03)).
Conclusions: Individuals with hMSH2 deficient CRC in the general population exhibit a family history and
other characteristics suggestive of HNPCC, and may carry germline MMR mutations. Loss of hMLH1 is only
associated with a strong family history of extracolonic cancer at older ages, suggesting a novel mechanism
of susceptibility.
A
pproximately 5% of all colorectal cancers (CRCs) are
thought to arise as a result of familial adenomatous
polyposis or hereditary non-polyposis colorectal cancer
(HNPCC). Although these dominantly inherited cancer
susceptibility syndromes account for only a small proportion
of CRCs in general, they are of significance because of their
associated high cancer risk. Furthermore, their study has
greatly increased our understanding of the molecular events
driving CRC development. In comparison, familial aggrega-
tion of CRC within families in the absence of a recognisable
inherited trait is common. Numerous studies have noted that
10–20% of individuals affected by CRC report a close family
member also affected by the disease.1 2 It is estimated that
close relatives of individuals affected by CRC have a two- to
fivefold increased risk of developing CRC themselves.3 Cancer
risk increases with the number of first degree relatives
affected, and is particularly high if a first degree relative
develops CRC under the age of 45 years.4 5 Similar studies
have reported a close association between family history of
CRC and the development of colorectal adenomas.6 7
HNPCC is characterised by the development of cancer
affecting the gastrointestinal, female reproductive, and
urinary tracts.8 Cancers often occur at a young age, are often
multiple, and when arising in the colon are frequently
proximal in location. However, there is no characteristic
phenotype associated with HNPCC, and diagnosis is depen-
dent on recognition of a strong family history suggestive of
dominant inheritance.
HNPCC is known to result from inherited deficiency of
mismatch repair (MMR). Human MMR is mediated by a
number of genes, including hMLH1, hMSH2, hMSH6,
hPMS1, hPMS2, hMLH3, and hMSH3.9–11 Together these
genes are responsible for recognising and initiating repair of
mismatched base pairs. Failure of any component of MMR
has the potential to allow incorporation of unrecognised base
pair mismatches into the genome. This process may be
sufficient to affect subsequent expression of genes that are
essential to normal cell function, regulation, and growth.12
Mismatching of base pairs commonly occurs through somatic
mutation in microsatellite DNA sequences which consist of
simple nucleotide repeats.13 The resulting microsatellite
instability (MSI) is a characteristic of MMR deficiency and
is found in the majority of CRCs arising in HNPCC.14 15 To
date, germline mutations affecting hMLH1,16 17 hMSH2,18 19
hPMS1, hPMS2,20 and hMSH621 have been documented in
HNPCC families.
Deficiency of MMR is also known to play a role in the
development of CRC more generally. MSI is found in
approximately 15% of all CRCs,13 14 particularly those located
in the proximal colon.22 The significance of MSI in such
cancers is unclear. It may be assumed that some cases
represent unrecognised HNPCC (that is, in association with
germline mutations, even in the absence of a clear family
history). However, in the majority of sporadic CRCs, MMR
deficiency is thought to be an acquired event, resulting from
somatic mutation or abnormal DNA methylation.23 24 It is not
clear whether the events leading to loss of MMR truly occur
by chance or whether some individuals are susceptible to the
development of such abnormalities. This study examines the
Abbreviations: MMR, mismatch repair; HNPCC, hereditary non-
polyposis colorectal cancer; CRC, colorectal cancer; MSI, microsatellite
instability; OR, odds ratio
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relationship between family history of cancer and develop-
ment of MMR deficient CRC.
METHOD
Study population
Two CRC populations were identified. Appropriate ethics
approval was obtained and members of each group provided
informed consent for participation in this study. Char-
acteristics of the study populations are detailed below.
Hospital based group
Individuals with histologically proven CRC were identified
from the outpatient clinic of a single CRC surgeon. Patients
diagnosed consecutively between 1987 and 1999 were
approached to participate. If the affected patient was
deceased, permission to include that patient in the study
was sought from the next of kin.
Population based group
This group consisted of patients recruited to a multicentre
case control study of diet. Eligible patients had histologically
confirmed CRC reported to the Yorkshire Cancer Registry
between September 1997 and October 1999. All cases were
aged between 45 and 80 years, were resident within Leeds,
and were treated within the Leeds Teaching Hospitals. The
case control study excluded all individuals with a previous
diagnosis of cancer, cancer arising in the context of familial
polyposis coli, inflammatory bowel disease, or suggestive of
metastatic spread.
Assessment of family history
After permission was obtained from their general practi-
tioners and/or hospital consultants, individuals from the two
CRC study groups were invited to attend for personal
interview to assess family history. If the proband was
deceased, next of kin were approached. Interviews were
undertaken by trained interviewers, with emphasis placed on
reports of cancer in first degree relatives (parents, siblings,
and children). Particular attention was paid to diagnoses of
HNPCC spectrum cancer (colon and rectum, stomach, small
bowel, hepatobiliary tract, female reproductive tract, and
urinary tract). Cancer diagnoses in relatives were verified
against pathology reports, hospital notes, death certificates,
or cancer registry records.
Demographic data (current age, age at diagnosis, sex) was
recorded for all first degree relatives. Pedigrees were also
assessed for features of dominantly inherited cancer suscept-
ibility suggestive of HNPCC using the Amsterdam criteria (I
and II) and modified ICG-HNPCC diagnostic criteria outlined
in table 1. Details of family history in the hospital based
group have been reported in part previously.25–27
Immunohistochemical analysis
Tissue ascertainment
Paraffin embedded tissue from the identified CRC was
obtained for all patients. Tissue sections, each 4 mm, were
selected for each tumour that contained both CRC tissue and
normal colonic mucosa.
Immunohistochemical assessment of hMLH1 and
hMSH2 expression
Expression of hMLH1 and hMSH2 was assessed using an
immunohistochemical technique reported previously.28 Tissue
sections were deparaffinised with xylene and rehydrated
through graded alcohols to water. Endogenous peroxidase
was blocked using 3% (v/v) hydrogen peroxide in methanol
for 20 minutes. Antigenic site retrieval was achieved by
boiling in 1.5 litres of 1:100 antigen unmasking solution
(Vector Laboratories, Peterborough, UK) at 103 kPa for
90 seconds. Subsequent immunohistochemical reactions
were performed using the Sequenza system (Shandon,
Basingstoke, UK). Non-specific antibody binding was pre-
vented by incubation with 1% casein (Vector Laboratories) in
Tris buffered saline (pH 7.6) for 10 minutes. Endogenous
biotin was then blocked using the avidin/biotin blocking kit
(Vector Laboratories), each applied for 15 minutes. Tissue
sections were then incubated with monoclonal hMSH2
antibody (Calbiochem, Nottingham, UK) or monoclonal
hMLH1 (Pharmingen, San Diego, California, USA) overnight
at 4 C˚. Antibodies were made up in a solution of 0.2% casein
in Tris buffered saline (pH 7.6), obtaining a final dilution of
1:100 hMSH2 and 1:70 hMLH1. A third slide, not treated
with either hMLH1 or hMSH2, served as a negative control.
Tissue bound hMSH2 and hMLH1 were identified by addition
of a secondary antibody, using the StreptABComplex/HRP
Duet Kit (Dako Ltd, High Wycombe, UK), and then visualised
using 0.01% 3,39-diaminobenzidine in Tris buffered saline.
Diaminobenzidine staining was intensified using 0.5% copper
sulphate in 0.9% saline for five minutes. Sections were then
counterstained with haematoxylin.
Assessment of MMR gene expression
All tissue sections were examined using a light microscope
for nuclear staining of hMLH1 and hMSH2 protein.
Expression was recorded as normal when nuclear staining
was observed. Expression was considered abnormal when
nuclear staining in cancer tissue was entirely absent in the
presence of normal mucosal and/or lymphoid staining.
Inclusion of normal mucosa in each tissue section thus
served as an internal control. Staining was reviewed
independently by LC or RC, and then re-reviewed jointly by
LC and RC. Examples of staining patterns can be found
elsewhere.28
Table 1 Characteristics of colorectal cancer (CRC) cases presenting to the Leeds
Teaching Hospitals, 1987–1999, with family history data and immunohistochemical
results
Total Hospital series Population series
Total number of cases 732 509 (69.5) 223 (30.5)
Sex
Male (%) 417 285 (56.0) 132 (59.2)
Female (%) 315 224 (44.0) 91 (40.8)
Age at diagnosis of CRC (y)
Median 68 69 67
Range 27–93 27–93 45–80
Tumour location
Proximal (%) 183 (25.0) 127 (25.0) 56 (25.1)
Distal (%) 549 (75.0) 382 (75.0) 167 (74.9)
MMR and family history of colorectal cancer 637
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Statistical analysis
Differences in sex and tumour location and reported family
history between the two study groups were compared using a
two sided x2 analysis and/or Fisher’s exact test. Age at
diagnosis was compared using the Kruskal-Wallis equality of
populations test. The association between loss of expression
of hMLH1 and hMSH2 and family history of HNPCC
spectrum cancer was assessed using single and multiple
logistic regression. Initially the impact of each putative risk
factor (for example, age, sex, anatomical location, family
history) was assessed separately with logistic regression. As
many of these risk factors are interrelated (for example, sex
and anatomical location of tumour), we used multiple logistic
regression to identify the independent effects of each putative
risk factor. Odds ratios (OR) were used as measures of
association, together with the associated 95% confidence
intervals (CI).
Relative risk estimates, together with the Poisson prob-
ability for the relative risk of colorectal and HNPCC spectrum
extracolonic cancer in first degree relatives, were calculated
by comparing the observed incidence of cancer in the study
populations with an expected cancer incidence based on
cancer incidence rates in the general population (obtained
from the Yorkshire Cancer Registry for the years 1984–1986).
Years at risk were determined from current age, age at death,
or age at diagnosis of cancer.
Statistical significance was assumed where p(0.05. All
statistical analyses were performed using the Stata statistical
software package (College Station, Texas, USA).
RESULTS
Population demographics
Hospital based CRC group
A total of 909 cases of CRC were identified in the hospital
based group. All cases were diagnosed between 1987 and
1999. Of these, 644 (70.8%) underwent interview to assess
family history. Colorectal cancer tissue was obtained for 516
(80.1% of those interviewed) cases with a known family
history, and 509 were successfully stained for hMLH1 and
hMSH2.
Population based case control group
A total of 452 residents of Leeds diagnosed with CRC were
reported during the recruitment phase of the case control
study detailed above. Two hundred and three cases were
subsequently found to be ineligible for further study on the
basis of age, coexisting or previous disease, ethnic back-
ground, or declined the invitation to participate. The
remaining 249 individuals comprise the population based
case control group although 24 were already part of the
hospital based case group and are included in that dataset for
this analysis. All cases were aged 45–80 years at the time of
diagnosis. All cases underwent interview to assess family
history. CRC tissue was obtained for the 226 remaining cases
and 223 (98.7%) were successfully stained for hMLH1 and
hMSH2.
Characteristics of the study groups are compared in table 1.
Both groups were comparable for sex and tumour location.
Thirty four (5.3%) hospital based cases were found to have
Table 2 Family history characteristics of 732 patients presenting to the Leeds Teaching
Hospitals with colorectal cancer, 1987–1999, with family history data and
immunohistochemical results
Total Hospital series Population series p Value
FDR with CRC 142 (19.4) 102 (20.0) 40 (17.9) 0.54*
No of affected FDRs
0 590 (80.6) 407 (80.0) 183 (82.1)
1 121 (16.5) 88 (17.3) 33 (14.8)
2 or 3 21 (2.9) 14 (2.7) 7 (3.1) 0.39
FDR with extracolonic cancer* 87 (11.9) 65 (12.8) 22 (9.9) 0.32*
No of affected FDRs
0 645 (88.1) 444 (87.2) 201 (90.1)
1 76 (10.4) 56 (11.0) 20 (9.0)
2 or 3 11 (1.5) 9 (1.8) 2 (0.9) 0.63`
FH suggestive of HNPCC
Total 19 (2.6) 14 (2.7) 5 (2.2)
None 713 (97.4) 495 (97.3) 218 (97.8)
Amsterdam 6 (0.8) 6 (1.2) 0 (0)
Modified 13 (1.9) 8 (1.6) 5 (2.7) 0.07`
CRC, colorectal cancer; FDR, first degree relative; HNPCC, hereditary non-polyposis colorectal cancer; FH, family
history.
*x2 p value compares reports of CRC and extracolonic cancer in relatives of CRC cases identified from hospital and
population series.
p value compares number of CRC and extracolonic cancer cases between hospital and population series.
`p value from Fisher’s exact test.
p value compares number of family history pedigrees meeting HNPCC criteria between study groups.
Table 3 Clinical criteria for suspicion of hereditary non-
polyposis colorectal cancer (HNPCC).39 Revised ICG-
HNPCC criteria (Amsterdam I and II)
There should be at least 3 relatives with CRC, or there should be at least 3
relatives with an HNPCC associated cancer (CRC, endometrium, small
bowel, ureter, or renal pelvis); all the following should be present:
l One should be a first degree relative of the other two
l At least 2 successive generations should be affected
l At least 1 CRC should be diagnosed before the age of 50
l Familial adenomatous polyposis should be excluded
l Tumours should be verified by pathological examination
ICG, International Collaborative Group; CRC, colorectal cancer.
Table 4 Criteria for suspicion of hereditary non-
polyposis colorectal cancer (HNPCC) based on ICG
definition of HNPCC (Lynch syndrome)
l Familial clustering of CRC and/or endometrial cancer (2 first degree
relatives across 2 generations, with further affected second degree
relatives)
l Associated cancers of: stomach, ovary, ureter/renal pelvis, small
bowel, hepatobiliary tract, skin (sebaceous tumours)
l Development of cancer at an early age
l Development of multiple cancers, particularly multiple CRCs
l Proximal location of CRC
ICG, International Collaborative Group; CRC, colorectal cancer.
638 Coggins, Cawkwell, Bell, et al
www.gutjnl.com
 on 8 June 2005 gut.bmjjournals.comDownloaded from 
synchronous tumours or occurred in individuals previously
affected by a primary HNPCC spectrum cancer. Median age at
the time of diagnosis of CRC was lower in the population
based group by 1.3 years (p=0.07, Kruskal-Wallis equality of
populations test). This reflects exclusion of individuals over
80 years of age in the population based group.
Family history characteristics
Information was obtained regarding 4824 first degree
relatives. Of these, 683 (%) were reported to have been
affected by cancer and 207 (38.1%) of these cancers were
from the HNPCC spectrum. One hundred and eighty eight
(69.9%) were subsequently confirmed against the cancer
register, case notes, death certificates, or pathology records.
There was no difference in age at diagnosis between the
HNPCC spectrum cancer group and the confirmed cancer
subgroup (mean ages 66.0 and 65.9 years, respectively (range
27–95); p=0.53).
Family history characteristics for the study groups are
summarised in table 2. There were no significant differences
in family history between the two study groups. Family
history of CRC (first degree relatives only) was reported in
20.0% and 17.9% of patients in the hospital based and
population based groups, respectively (test of equality,
p=0.52 by x2 test). First degree relatives affected by
HNPCC spectrum extracolonic cancer were reported in
12.8% of hospital based and 9.8% of population based
patients (test of equality, p=0.25 by x2 test). Overall, a first
degree relative affected by CRC was reported by 19.3% of the
combined hospital and population based groups while 11.9%
reported a first degree relative affected by extracolonic
cancer. There was one individual with more than two first
degree relatives with CRC while one patient (0.2%) reported
three first degree relatives affected by extracolonic cancer.
Nineteen patients (2.6%) gave a family history that was
suggestive of HNPCC. Of these, six (0.8%) met the
Amsterdam criteria while 13 (1.8%) met the revised
Amsterdam (II) criteria or were suspicious of HNPCC using
modified diagnostic criteria.
hMLH1 and hMSH2 expression in CRC
hMLH1 and hMSH2 expression was assessed in a total of 732
CRCs from the combined study groups. Six hundred and
seventy five (92.0%) CRCs exhibited normal expression of
both hMLH1 and hMSH2. Of the 57 (8.0%) remaining CRCs,
52 (7.1%) showed no staining for hMLH1 while just five
(0.9%) demonstrated loss of hMSH2. Loss of expression was
similar in both study groups (Fisher’s exact test, p=1.0).
Using univariate logistic regression, loss of expression of
hMLH1 in CRC tissue was associated with sex (male
compared with female: OR 0.49 (95% CI 0.27–0.86);
p=0.01) and proximal location (proximal compared with
distal: OR 25.02 (95% CI 11.04–56.69); p,0.0001). A second
HNPCC spectrum cancer was associated with an OR of 2.38
(95% CI 0.88–6.42; p=0.09). Loss of hMLH1 was more
common with increasing age at diagnosis (OR 1.05 (95% CI
1.02–1.08); p=0.001 for each increasing year). Loss of
expression of hMSH2 was non-significantly associated with
female sex (OR 0.18 (95% CI 0.02–1.68); p=0.13) and the
presence of a second HNPCC spectrum cancer (OR 32.8 (95%
CI 7.03–153.11); p,0.0001). All hMSH2 deficient CRCs were
located in the proximal colon. In contrast with hMLH1
deficient tumours, loss of hMSH2 was less common with
increasing age (OR 0.93 (95% CI 0.87–1.00); p=0.06 for each
increasing year).
Amsterdam criteria and loss of expression
Nineteen cases had a family history consistent with one of
the definitions of HNPCC in tables 3 and 4. Of these, two
(10.5%) had loss of expression of hMSH2 and two (10.5%) of
hMLH1. All four of the tumours were right sided. The two
cases with hMSH2 loss of expression each had a second
HNPCC primary (renal pelvis and ovary) plus a family history
of CRC and endometrial cancer. One case with hMLH1 loss of
expression had a family history of CRC, stomach cancer, and
pancreatic cancer while the second had a family history of
stomach cancer, pancreatic cancer, and endometrial cancer.
Family history and hMLH1 and hMSH2 expression
Of the five cases with loss of expression for hMSH2, two had
a family history satisfying the modified Amsterdam criteria
(see previous section). For hMLH1, nine of the 52 (17.3%)
cases with loss of expression had a family history compared
with 196 of 484 (28.8%) of those without loss of expression
(p=0.07 for equal proportions). Family history character-
istics of MMR proficient and hMLH1 and hMSH2 deficient
CRC are summarised in tables 5–7. Extent of family history
was assessed as any first degree relative with cancer and
Table 5 Association between mismatch repair gene expression and family history of
colorectal and extracolonic cancer based on univariate logistic regression
Loss of hMLH1 Loss of hMSH2
OR 95% CI p Value OR 95% CI p Value
Colorectal cancer
FDR with CRC` 0.53 0.22–1.26 0.15 1.05 0.12–9.45 0.97
No of affected FDRs
0` 1.00 1.00
1 0.52 0.20–1.32 0.17 0.00 – 0.37
2 or 3 0.59 0.08–4.51 0.61 7.34 0.78–68.66 0.08
Extracolonic cancer
FDR with extracolonic cancer*` 0.96 0.40–2.33 0.94 5.04 0.83–30.57 0.08
No of affected FDRs
0` 1.00 1.00
1 0.54 0.16–1.76 0.30 5.78 0.95–35.18 0.06
2 or 3 4.88 1.25–19.03 0.02 0.00 – 0.82
FH suggestive of HNPCC
None 1.00 1.00
Amsterdam (I and II) or modified 1.56 0.35–6.94 0.56 27.84 4.37–177.56 ,0.0001
OR, odds ratio; CI, confidence interval; CRC, colorectal cancer; FH, family history; FDR, first degree relative;
HNPCC, hereditary non-polyposis colorectal cancer.
*FH of HNPCC spectrum extracolonic cancer.
Odds ratios, confidence intervals, and p values refer to loss of expression of hMLH1 and hMSH2 compared with
`individuals with no affected FDR.
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number of affected first degree relatives. Table 5 summarises
odds ratios for MMR deficient CRC based on family history of
colorectal and HNPCC spectrum extracolonic cancer using
univariate logistic regression. Table 6 summarises odds ratios
for MMR deficient CRC using a multivariate logistic regres-
sion analysis. Table 7 summarises relative cancer risk in first
degree relatives of patients with MMR proficient and hMLH1
and hMSH2 deficient CRC.
In table 5, there was no association between loss of hMLH1
or hMSH2 and family history of CRC overall (p=0.15 for
hMLH1, p=0.97 for hMSH2). In the presence of multiple
affected relatives, this comparison approached significance
for hMSH2 (OR 7.34 (95% CI 0.78–68.7); p=0.08). For
extracolonic tumours, there was no association with loss of
expression of hMLH1 (p=0.94) except for the category of
two or more affected relatives (OR 4.88 (95% CI 1.25–19.03);
p=0.02). For hMSH2, the risk for those with a family history
approached significance (OR 5.04 (95% CI 0.83–30.57);
p=0.08); this effect was all due to the family history of
one extracolonic cancer.
The association between hMLH1 deficient CRC and family
history of HNPCC extracolonic cancer was seen to be more
marked using a multivariate logistic regression analysis
(including adjustment for tumour location, sex, age at
diagnosis, and family history suggestive of HNPCC: OR 9.15
(95% CI 1.18–70.84); p=0.03) (table 6). This association was
seen whether or not HNPCC type family history was adjusted
for (data not shown). These findings suggest that the
observed association between family history of HNPCC
spectrum extracolonic cancer and hMLH1 deficient CRC is
independent of clinically recognisable HNPCC based on
family history assessment. However, the effect of family
history on hMSH2 loss of expression in multivariate analysis
was reduced (from that in the univariate analysis) after
adjusting for a family history suggestive of HNPCC.
Assessment of family history using Amsterdam criteria (I
and II) or modified Amsterdam criteria identified that while
loss of hMSH2 was clearly associated with a family history
suggestive of HNPCC (OR 27.84 (95% CI 4.37–177.56);
p,0.0001), such a history was not predictive of loss of
hMLH1 (OR 1.56 (95% CI 0.35–6.94); p=0.56).
Table 7 summarises relative cancer risk in first degree
relatives of CRC cases. Relatives were seen to be at increased
risk of developing CRC (relative risk 1.63, p,0.0001). Cancers
of the stomach, ovary, uterus, and pancreas were seen to
occur at the same incidence as in the reference population.
Relative cancers risks were seen to be similar in relatives of
individuals with MMR proficient CRC. Relatives of indivi-
duals with hMSH2 deficient CRC were at increased risk of
uterine cancer (relative risk 25.0, p=0.003). Although
relative risk of CRC was also raised (relative risk 2.70), this
was not statistically significant. Relatives of individuals with
hMLH1 deficient CRC were not seen to be at increased risk of
any cancer.
DISCUSSION
This study has detailed the family history characteristics of a
large cohort of CRC patients. This cohort was of significance
in that cases were identified consecutively and, we believe,
can be assumed to be representative of the CRC population in
general. Accordingly, CRC cases included in this study were
predominantly distal in location, were equally distributed by
sex, and occurred at a median age of 70 years.
Familial clustering of CRC is a consistent finding in
epidemiological studies.4 29 30 Although it is recognised that
recall of family events can be unreliable,31 70% of cancers
considered of interest in this study were subsequently
confirmed against cancer registry or hospital records.
However, reports of other cancers outside the HNPCC
spectrum were less reliable, with only 39% confirmed. This
may, in part, reflect a bias towards confirmation of those
cancers considered significant in the setting of familial CRC.
There has been less attention paid in the literature to the
association between CRC and family history of extracolonic
cancer. There is evidence that close relatives of individuals
with CRC are also at increased risk of developing cancer of
the uterus, ovary, stomach, and breast.32–34 In this study,
HNPCC spectrum extracolonic cancer was reported in 5.1% of
first degree relatives.
The incidence of HNPCC in the general population is
difficult to estimate. While generally quoted as 5% of all
CRCs, numerous studies estimate the HNPCC prevalence to
be much lower.35 36 In this study, HNPCC assessed by family
history alone was estimated to be 2.6%. Six families (0.8%)
met the Amsterdam criteria (I and II) while a further 13
(1.8%) were thought to represent HNPCC based on modified
criteria.
Germline mutations in DNA MMR genes play a causative
role in the development of CRC through HNPCC. Modelling
has suggested that the familial risk is not due entirely to
HNPCC,37 raising the possibility that MMR abnormalities play
a broader role in susceptibility. Alternatively, acquired
mutations may be more common in certain individuals
rendered susceptible, perhaps by the interaction of inherited
Table 6 Association between mismatch repair gene expression and family history of
colorectal and extracolonic cancer based on multivariate logistic regression
Loss of hMLH11 Loss of hMSH2
OR 95% CI p Value OR 95% CI p Value
FDR with CRC` 0.47 0.18–1.25 0.13 0.16 0.01–3.13 0.23
No of affected FDR
0` 1.00 1.00
1 0.46 0.16–1.29 0.14 – – –
2 or 3 0.55 0.06–5.14 0.60 0.40 0.02–9.79 0.57
FDR with extracolonic cancer*` 0.97 0.32–2.95 0.96 2.20 0.23–20.96 0.49
No of affected FDR
0` 1.00 1.00
1 0.61 0.16–2.27 0.46 2.59 0.27–24.89 0.41
2 or 3 9.15 1.18–70.84 0.03 – – –
OR, odds ratio; CI, confidence interval; CRC, colorectal cancer; FH, family history; FDR, first degree relative.
*FH of HNPCC spectrum extracolonic cancer.
Odds ratios, confidence intervals, and p values refer to loss of expression of hMLH1 and hMSH2 compared with
`individuals with no affected FDR.
Adjusted for age at diagnosis, sex, and family history suggestive of HNPCC (not adjusted for tumour location as
all tumours were right sided).
1Adjusted for tumour location, age at diagnosis, sex, and family history suggestive of HNPCC.
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polymorphic genes and environmental exposure. Eight per
cent of cancers in this study were shown to be deficient in
MMR. A small proportion of these cancers could represent
HNPCC cases but there was no evidence of an association
between loss of MMR and family history of CRC except for
multiple affected relatives and hMSH2. These findings are in
keeping with previous studies.27 38 In comparison, however,
there is evidence of an association between MMR deficient
CRC and family history of HNPCC spectrum extracolonic
cancer. Loss of hMLH1 and hMSH2 was approximately five
times more common in individuals with a family history of
extracolonic cancer (of two or three relatives for hMLH1 or
one relative for hMSH2), compared with those with no family
history. The general characteristics of hMSH2 deficient CRC
(proximal location, young age at diagnosis, association with
development of multiple primary cancers, and association
with family history suggestive of HNPCC) are consistent with
causative germline mutations. hMLH1 deficient CRCs identi-
fied in this study do not exhibit characteristics suggestive of
HNPCC. In contrast with hMSH2 deficient cancer, hMLH1
deficient CRCs tend to occur at a later age (75.0 years of age
for those with a family history of colorectal or HNPCC
spectrum) and in the absence of a family history suggestive of
HNPCC. The observed association between hMLH1 deficient
CRC and family history of HNPCC spectrum extracolonic
cancer persists with or without inclusion of HNPCC-like
characteristics in a multivariate analysis, suggesting that loss
of hMLH1 in CRC occurs independently of germline MMR
mutations. These data therefore suggest another mechanism
predisposing to loss of hMLH1 in individuals with a family
history of extracolonic cancer. An example of such a putative
mechanism would be susceptibility to promoter methylation
as methylation is known to be associated with loss of
expression of hMLH1.23 24 Such an observation of promoter
hypermethylation of hMLH1 has been made for adenoma-
tous polyps found in close relatives of patients with CRC.40
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